Search Results Label

Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.

https://www.seqirus.us/expertise/influenza

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.us/expertise

Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community.

https://www.seqirus.us/products

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-announces-late-breaking-data-at-idweek-2020

Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020

https://www.seqirus.us/news/seqirus-presents-real-world-data-for-cell-based-quadrivalent

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-presents-new-real-world-evidence-on-relative-effectiveness

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-publishes-new-real-world-evidence

Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market

https://www.seqirus.us/news/seqirus-ships-2020-2021-influenza-vaccines-to-us-market

Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Benefits of MF59®-Adjuvanted Seasonal Influenza Vaccine

https://www.seqirus.us/news/seqirus-presents-new-late-breaking-data-at-eswi-2020

Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity of Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine

https://www.seqirus.us/news/seqirus-presents-new-data-at-eswi-2020-demonstrating-safety-and-immunogenicity